0
New
New
2023
Personalized Medicine Market

Personalized Medicine Market

by Product (Personalized Medicine Therapeutics, Personalized Medicine Diagnostics), by Application (Oncology, Infectious disease, Neurology or Psychiatry, Cardiovascular, Others), by End User (Hospitals and Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A13388
Mar 2023 | Pages: 286
Tables: 122
Charts: 67
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Personalized Medicine Market Research, 2031

The global personalized medicine market size was valued at $300 billion in 2021 and is projected to reach $869.5 billion by 2031, growing at a CAGR of 11.2% from 2022 to 2031. Personalized medicine, also known as precision medicine, is an approach to healthcare that involves tailoring medical treatment to the individual characteristics of each patient. This approach recognizes that every patient is unique and that treatments that work for one patient may not work for another.

Personalized medicine aims to use an individual's specific genetic makeup, lifestyle, and medical history to develop more effective and targeted treatments. In personalized medicine, healthcare providers use advanced diagnostic tests and tools to identify genetic variations or other biomarkers associated with specific diseases. By analyzing this information, the healthcare provider can develop personalized treatment plans that are tailored to the specific needs of each patient. In addition, personalized medicine is a rapidly evolving field that has the potential to transform healthcare by improving the accuracy and effectiveness of medical treatments, reducing healthcare costs, and improving patient outcomes.

COVID-19 pandemic had a positive impact on the personalized medicine market owning to rise in demand for personalized diagnostic services and rise in use of genetic testing to identify patients with increased risk of corona virus infection. In addition, personalized medicine approaches were used to develop targeted therapies for COVID-19 based on the patient's individual characteristics, which boosted the market growth.

Personalized Medicine Market

Market dynamics
Growth of the personalized medicine market size is mainly attributed to the rise in prevalence of chronic conditions such as cancer, diabetes, and others. Increase in prevalence of these conditions increases the demand for personalized diagnostic and personalized therapeutics solutions. In addition, presence of large number of key players in the market is further expanding the market growth. Aadi Bioscience, Inc., Abott, ARIEL Precision Medicine, Inc., Atlas Biomed Group Limited, BASF SE and others are few of the key players offering personalized medicine solutions. These key players are adopting various growth strategies to expand its business and remain in competition with other key players. For instance, in January 2021, Roche announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis for breast cancer for precision patient diagnosis in breast cancer. More such product offering, and strategies adopted by the key players is boosting the market growth. 

In addition, companion diagnostics, an important component of personalized medicine, allows for the identification of patients who are likely to benefit from a particular treatment, and also help to monitor the patient's response to that treatment over time. By using companion diagnostics, physicians can make more informed decisions about which treatments are most appropriate for the patients, and adjust those treatments as necessary based on the patient's individual response. Thereby driving the personalized medicine market growth.

Although various factors are driving the growth of the market, factor such as lack of awareness about personalized medicine among the population in underdeveloped countries is causing hindrance to the market growth. In addition, high cost of the therapies makes it inaccessible for the people in poor countries, which further acts as a restraint to the market growth. 

The global market for personalized medicine expanded as a result of the COVID-19 outbreak. Although the COVID-19 pandemic had a significant impact on healthcare systems around the world, personalized medicine's incorporation into clinical care had a huge potential to enhance disease identification and management. The COVID-19 infection had a wide range of symptoms, from mild infections to serious potentially fatal symptoms.

Moreover, due to individual susceptibility to infection as well as inter-individual variability in course of illness, prognosis, and treatment response, personalized medicine gained a significant attention during the pandemic. 
Although the pandemic had a favorable effect on the market for personalized medicine during that period, there was a decline in the number of people visiting hospitals for conditions other than COVID-19, which had a slight negative effect on the market. However, as targeted medicines and vaccinations are now being developed for the prevention of such outbreaks, it is anticipated that the personalized medicine industry would expand after the pandemic. This will boost market expansion in the near future.

Segmental Overview
The personalized medicine industry is segmented on the basis of product, application, and region. By product, the market is categorized into personalized medicine diagnostics, and personalized medicine therapeutics. On the basis of application, the market is segregated into oncology, infectious disease, neurology or psychiatry, cardiovascular and others. On the basis of end user, the market is segmented into hospitals & clinics, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is further analyzed across U.S., Canada and Mexico, Europe is analyzed across UK, Germany, France, Italy, Spain and Rest of Europe. Asia-Pacific is studied across Japan, China, Australia, and Rest of Asia-Pacific and LAMEA is studied in Latin America and Middle East & Africa. 

By Product: The personalized medicine diagnostics segment dominated the global personalized medicine market share in 2021, and is anticipated to drive the market during the forecast period, owing to the growing burden of chronic diseases such as cancer, diabetes, and cardiovascular disease, and subsequent rise in demand for personalized medicine diagnostics for its detection. Also, rising awareness among the people and healthcare providers about advanced personalized medicine solutions is boosting the segment growth.

Personalized Medicine Market

By Application: The oncology segment dominated the global market in 2021, and is anticipated to continue this trend during the forecast period, which is attributed the increasing demand for personalized medicines in cancer treatment. In addition, personalized medicine allows for precise diagnosis of cancer at the molecular level, which helps healthcare providers to identify the specific genetic mutations or other biomarkers driving the cancer. This boosts the personalized medicine market growth. On the other hand, cardiovascular segment is anticipated to grow at a fastest rate during the forecast period, owing to the increase in prevalence of CVS disorders and rise in adoption of personalized medicines in its treatment.

Personalized Medicine Market

By End User: On the basis of end user, hospitals & clinic segment dominated the market in terms of revenue in 2021, owing to the specialized facilities offered by hospitals for personalized treatments and solutions for various diseases. On the other hand, others segment is anticipated to grow a fastest rate during the personalized medicine market forecast, owing to rise in investment by the pharma and biotech companies in personalized medicines fields and wide product offering by the diagnostic tool companies in personalized medicines.

Personalized Medicine Market

By region: The personalized medicine market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a major personalized medicine market share in 2021, and is expected to maintain its dominance during the forecast period. The presence of several major players, such as Abbott, Qiagen, GE Healthcare and BASF SE is the prime factor boosting the growth of personalized medicine market in this region. In addition, the high prevalence of chronic diseases such as cancer, cardiovascular disease, and diabetes in North America, is increasing the demand for personalized medicines solutions that can provide more targeted and effective treatments. 

Furthermore, North America has a highly advanced healthcare infrastructure, with a strong emphasis on innovation and the adoption of new technologies. This has enabled the development and widespread adoption of personalized medicine technologies in the region. 

Asia-Pacific expected to grow at the highest rate during the personalized medicine market forecast. The market growth in this region is attributable to presence of pharmaceutical companies in the region as well as growth in the purchasing power of populated countries, such as China and India. Moreover, rise in personalized medicine expenditure and adoption of high-tech processing to improve the production of personalized solutions, is anticipated to drive the growth of the market.  Furthermore, Asia-Pacific region has a large and growing population, which is driving demand for more personalized healthcare solutions, including personalized medicines. Also, the prevalence of chronic diseases such as cancer, cardiovascular disease, and diabetes is increasing in the Asia-Pacific region, which is driving demand for more effective and targeted treatments.  

 

Personalized Medicine Market

COMPETITION ANALYSIS
Competitive analysis and profiles of the major players in the personalized medicine market, such as Aadi Bioscience, Inc., Abbott Laboratories, ARIEL Precision Medicine, Inc., Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Takeda Pharmaceutical Company Ltd, Eli Lilly and Company, Abbvie Inc. and Qiagen are provided in this report. Major players have adopted product launch, product approval, partnership, acquisition, collaboration, branding, expansion and others as key developmental strategies to improve the product portfolio of personalized medicines. 

Product approvals in the personalized medicine market

  • In January 2020, Abbott received approval from the U.S. Food and Drug Administration (FDA) for Infinity Deep Brain Stimulation (DBS) system to target an area of the brain called the internal globus pallidus. With this approval, Abbott continues to advance its Infinity DBS system to provide personalized and patient-centric innovations for people with movement disorders.

Recent product launches in the personalized medicine market

  • In December 2021, Roche announced the launch of the AVENIO Edge System to advance sequencing technologies, built with best-in-class foundational capabilities to deliver a fully-automated, integrated sequencing solution and thus advance its precision medicine solutions.

Acquisitions in the personalized medicine market 

  • In January 2019, Qiagen announced the acquisition of N-of-One, a leader in identifying patient-specific therapeutic options for precision medicine in oncology, thereby expanding its clinical bioinformatics capabilities in molecular oncology decision support.

Strategic alliance in the personalized medicine market

  • In June 2020, Ariel Precision Medicine, Inc. announced an alliance with Mission Cure Holdings, LLC, and Path BioAnalytics, Inc. to develop innovative treatments for patients with pancreatitis and other rare diseases which there is currently no treatment.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the personalized medicine market analysis from 2021 to 2031 to identify the prevailing personalized medicine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the personalized medicine market segmentation assists to determine the prevailing market personalized medicine market opportunity.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global personalized medicine market trends, key players, market segments, application areas, and market growth strategies.

Personalized Medicine Market Report Highlights

Aspects Details
Market Size By 2031 USD 869.5 billion
Growth Rate CAGR of 11.2%
Forecast period 2021 - 2031
Report Pages 286
By Product
  • Personalized Medicine Therapeutics
    • Type
      • Pharmaceuticals
      • Genomic Medicines
      • Medical Devices
  • Personalized Medicine Diagnostics
By Application
  • Oncology
  • Infectious disease
  • Neurology or Psychiatry
  • Cardiovascular
  • Others
By End User
  • Hospitals and Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, Rest of Asia-Pacific)
  • LAMEA  (Latin America, Middle East And Africa)
Key Market Players Illumina, Inc., Aadi Bioscience, Inc., Takeda Pharmaceutical Company Ltd, Eli Lilly and Company, QIAGEN, F. Hoffmann-La Roche Ltd., Abbott Laboratories, ARIEL Precision Medicine, Inc., GE Healthcare,Inc, Abbvie Inc
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Bargaining power of suppliers

      • 3.3.2. Bargaining power of buyers

      • 3.3.3. Threat of substitutes

      • 3.3.4. Threat of new entrants

      • 3.3.5. Intensity of rivalry

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Surge in demand for personalized medicines
        • 3.4.1.2. Rise in prevalence of Cancer
        • 3.4.1.3. Rise in prevalence of chronic conditions in the population

      • 3.4.2. Restraints

        • 3.4.2.1. High cost of personalized medicines
        • 3.4.2.2. Lack of awareness regarding personalized medicines among population

      • 3.4.3. Opportunities

        • 3.4.3.1. Increase in healthcare expenditure with improvements in healthcare facilities
        • 3.4.3.2. Technological advancements in personalized medicines

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: PERSONALIZED MEDICINE MARKET, BY PRODUCT

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Personalized Medicine Therapeutics

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

      • 4.2.4. Personalized Medicine Therapeutics Personalized Medicine Market by Type

    • 4.3. Personalized Medicine Diagnostics

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

  • CHAPTER 5: PERSONALIZED MEDICINE MARKET, BY APPLICATION

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Oncology

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Infectious disease

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

    • 5.4. Neurology or Psychiatry

      • 5.4.1. Key market trends, growth factors and opportunities

      • 5.4.2. Market size and forecast, by region

      • 5.4.3. Market share analysis by country

    • 5.5. Cardiovascular

      • 5.5.1. Key market trends, growth factors and opportunities

      • 5.5.2. Market size and forecast, by region

      • 5.5.3. Market share analysis by country

    • 5.6. Others

      • 5.6.1. Key market trends, growth factors and opportunities

      • 5.6.2. Market size and forecast, by region

      • 5.6.3. Market share analysis by country

  • CHAPTER 6: PERSONALIZED MEDICINE MARKET, BY END USER

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Hospitals and Clinics

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Others

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

  • CHAPTER 7: PERSONALIZED MEDICINE MARKET, BY REGION

    • 7.1. Overview

      • 7.1.1. Market size and forecast By Region

    • 7.2. North America

      • 7.2.1. Key trends and opportunities

      • 7.2.2. Market size and forecast, by Product

      • 7.2.3. Market size and forecast, by Application

      • 7.2.4. Market size and forecast, by End User

      • 7.2.5. Market size and forecast, by country

        • 7.2.5.1. U.S.
          • 7.2.5.1.1. Key market trends, growth factors and opportunities
          • 7.2.5.1.2. Market size and forecast, by Product
          • 7.2.5.1.3. Market size and forecast, by Application
          • 7.2.5.1.4. Market size and forecast, by End User
        • 7.2.5.2. Canada
          • 7.2.5.2.1. Key market trends, growth factors and opportunities
          • 7.2.5.2.2. Market size and forecast, by Product
          • 7.2.5.2.3. Market size and forecast, by Application
          • 7.2.5.2.4. Market size and forecast, by End User
        • 7.2.5.3. Mexico
          • 7.2.5.3.1. Key market trends, growth factors and opportunities
          • 7.2.5.3.2. Market size and forecast, by Product
          • 7.2.5.3.3. Market size and forecast, by Application
          • 7.2.5.3.4. Market size and forecast, by End User
    • 7.3. Europe

      • 7.3.1. Key trends and opportunities

      • 7.3.2. Market size and forecast, by Product

      • 7.3.3. Market size and forecast, by Application

      • 7.3.4. Market size and forecast, by End User

      • 7.3.5. Market size and forecast, by country

        • 7.3.5.1. Germany
          • 7.3.5.1.1. Key market trends, growth factors and opportunities
          • 7.3.5.1.2. Market size and forecast, by Product
          • 7.3.5.1.3. Market size and forecast, by Application
          • 7.3.5.1.4. Market size and forecast, by End User
        • 7.3.5.2. France
          • 7.3.5.2.1. Key market trends, growth factors and opportunities
          • 7.3.5.2.2. Market size and forecast, by Product
          • 7.3.5.2.3. Market size and forecast, by Application
          • 7.3.5.2.4. Market size and forecast, by End User
        • 7.3.5.3. UK
          • 7.3.5.3.1. Key market trends, growth factors and opportunities
          • 7.3.5.3.2. Market size and forecast, by Product
          • 7.3.5.3.3. Market size and forecast, by Application
          • 7.3.5.3.4. Market size and forecast, by End User
        • 7.3.5.4. Italy
          • 7.3.5.4.1. Key market trends, growth factors and opportunities
          • 7.3.5.4.2. Market size and forecast, by Product
          • 7.3.5.4.3. Market size and forecast, by Application
          • 7.3.5.4.4. Market size and forecast, by End User
        • 7.3.5.5. Spain
          • 7.3.5.5.1. Key market trends, growth factors and opportunities
          • 7.3.5.5.2. Market size and forecast, by Product
          • 7.3.5.5.3. Market size and forecast, by Application
          • 7.3.5.5.4. Market size and forecast, by End User
        • 7.3.5.6. Rest of Europe
          • 7.3.5.6.1. Key market trends, growth factors and opportunities
          • 7.3.5.6.2. Market size and forecast, by Product
          • 7.3.5.6.3. Market size and forecast, by Application
          • 7.3.5.6.4. Market size and forecast, by End User
    • 7.4. Asia-Pacific

      • 7.4.1. Key trends and opportunities

      • 7.4.2. Market size and forecast, by Product

      • 7.4.3. Market size and forecast, by Application

      • 7.4.4. Market size and forecast, by End User

      • 7.4.5. Market size and forecast, by country

        • 7.4.5.1. Japan
          • 7.4.5.1.1. Key market trends, growth factors and opportunities
          • 7.4.5.1.2. Market size and forecast, by Product
          • 7.4.5.1.3. Market size and forecast, by Application
          • 7.4.5.1.4. Market size and forecast, by End User
        • 7.4.5.2. China
          • 7.4.5.2.1. Key market trends, growth factors and opportunities
          • 7.4.5.2.2. Market size and forecast, by Product
          • 7.4.5.2.3. Market size and forecast, by Application
          • 7.4.5.2.4. Market size and forecast, by End User
        • 7.4.5.3. Australia
          • 7.4.5.3.1. Key market trends, growth factors and opportunities
          • 7.4.5.3.2. Market size and forecast, by Product
          • 7.4.5.3.3. Market size and forecast, by Application
          • 7.4.5.3.4. Market size and forecast, by End User
        • 7.4.5.4. Rest of Asia-Pacific
          • 7.4.5.4.1. Key market trends, growth factors and opportunities
          • 7.4.5.4.2. Market size and forecast, by Product
          • 7.4.5.4.3. Market size and forecast, by Application
          • 7.4.5.4.4. Market size and forecast, by End User
    • 7.5. LAMEA

      • 7.5.1. Key trends and opportunities

      • 7.5.2. Market size and forecast, by Product

      • 7.5.3. Market size and forecast, by Application

      • 7.5.4. Market size and forecast, by End User

      • 7.5.5. Market size and forecast, by country

        • 7.5.5.1. Latin America
          • 7.5.5.1.1. Key market trends, growth factors and opportunities
          • 7.5.5.1.2. Market size and forecast, by Product
          • 7.5.5.1.3. Market size and forecast, by Application
          • 7.5.5.1.4. Market size and forecast, by End User
        • 7.5.5.2. Middle East And Africa
          • 7.5.5.2.1. Key market trends, growth factors and opportunities
          • 7.5.5.2.2. Market size and forecast, by Product
          • 7.5.5.2.3. Market size and forecast, by Application
          • 7.5.5.2.4. Market size and forecast, by End User
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top player positioning, 2021

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Abbott Laboratories

      • 9.1.1. Company overview

      • 9.1.2. Key Executives

      • 9.1.3. Company snapshot

      • 9.1.4. Operating business segments

      • 9.1.5. Product portfolio

      • 9.1.6. Business performance

      • 9.1.7. Key strategic moves and developments

    • 9.2. ARIEL Precision Medicine, Inc.

      • 9.2.1. Company overview

      • 9.2.2. Key Executives

      • 9.2.3. Company snapshot

      • 9.2.4. Operating business segments

      • 9.2.5. Product portfolio

      • 9.2.6. Key strategic moves and developments

    • 9.3. F. Hoffmann-La Roche Ltd.

      • 9.3.1. Company overview

      • 9.3.2. Key Executives

      • 9.3.3. Company snapshot

      • 9.3.4. Operating business segments

      • 9.3.5. Product portfolio

      • 9.3.6. Business performance

      • 9.3.7. Key strategic moves and developments

    • 9.4. GE Healthcare,Inc

      • 9.4.1. Company overview

      • 9.4.2. Key Executives

      • 9.4.3. Company snapshot

      • 9.4.4. Operating business segments

      • 9.4.5. Product portfolio

      • 9.4.6. Business performance

      • 9.4.7. Key strategic moves and developments

    • 9.5. Aadi Bioscience, Inc.

      • 9.5.1. Company overview

      • 9.5.2. Key Executives

      • 9.5.3. Company snapshot

      • 9.5.4. Operating business segments

      • 9.5.5. Product portfolio

      • 9.5.6. Business performance

      • 9.5.7. Key strategic moves and developments

    • 9.6. Illumina, Inc.

      • 9.6.1. Company overview

      • 9.6.2. Key Executives

      • 9.6.3. Company snapshot

      • 9.6.4. Operating business segments

      • 9.6.5. Product portfolio

      • 9.6.6. Business performance

      • 9.6.7. Key strategic moves and developments

    • 9.7. QIAGEN

      • 9.7.1. Company overview

      • 9.7.2. Key Executives

      • 9.7.3. Company snapshot

      • 9.7.4. Operating business segments

      • 9.7.5. Product portfolio

      • 9.7.6. Business performance

      • 9.7.7. Key strategic moves and developments

    • 9.8. Eli Lilly and Company

      • 9.8.1. Company overview

      • 9.8.2. Key Executives

      • 9.8.3. Company snapshot

      • 9.8.4. Operating business segments

      • 9.8.5. Product portfolio

      • 9.8.6. Business performance

    • 9.9. Takeda Pharmaceutical Company Ltd

      • 9.9.1. Company overview

      • 9.9.2. Key Executives

      • 9.9.3. Company snapshot

      • 9.9.4. Operating business segments

      • 9.9.5. Product portfolio

      • 9.9.6. Business performance

    • 9.10. Abbvie Inc

      • 9.10.1. Company overview

      • 9.10.2. Key Executives

      • 9.10.3. Company snapshot

      • 9.10.4. Operating business segments

      • 9.10.5. Product portfolio

      • 9.10.6. Business performance

  • LIST OF TABLES

  • TABLE 01. GLOBAL PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 02. PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY REGION, 2021-2031 ($BILLION)
    TABLE 03. GLOBAL PERSONALIZED MEDICINE THERAPEUTICS PERSONALIZED MEDICINE MARKET, BY TYPE, 2021-2031 ($BILLION)
    TABLE 04. PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY REGION, 2021-2031 ($BILLION)
    TABLE 05. GLOBAL PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 06. PERSONALIZED MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021-2031 ($BILLION)
    TABLE 07. PERSONALIZED MEDICINE MARKET FOR INFECTIOUS DISEASE, BY REGION, 2021-2031 ($BILLION)
    TABLE 08. PERSONALIZED MEDICINE MARKET FOR NEUROLOGY OR PSYCHIATRY, BY REGION, 2021-2031 ($BILLION)
    TABLE 09. PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR, BY REGION, 2021-2031 ($BILLION)
    TABLE 10. PERSONALIZED MEDICINE MARKET FOR OTHERS, BY REGION, 2021-2031 ($BILLION)
    TABLE 11. GLOBAL PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 12. PERSONALIZED MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 ($BILLION)
    TABLE 13. PERSONALIZED MEDICINE MARKET FOR OTHERS, BY REGION, 2021-2031 ($BILLION)
    TABLE 14. PERSONALIZED MEDICINE MARKET, BY REGION, 2021-2031 ($BILLION)
    TABLE 15. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 16. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 17. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 18. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
    TABLE 19. U.S. PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 20. U.S. PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 21. U.S. PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 22. CANADA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 23. CANADA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 24. CANADA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 25. MEXICO PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 26. MEXICO PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 27. MEXICO PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 28. EUROPE PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 29. EUROPE PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 30. EUROPE PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 31. EUROPE PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
    TABLE 32. GERMANY PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 33. GERMANY PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 34. GERMANY PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 35. FRANCE PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 36. FRANCE PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 37. FRANCE PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 38. UK PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 39. UK PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 40. UK PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 41. ITALY PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 42. ITALY PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 43. ITALY PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 44. SPAIN PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 45. SPAIN PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 46. SPAIN PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 47. REST OF EUROPE PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 48. REST OF EUROPE PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 49. REST OF EUROPE PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 50. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 51. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 52. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 53. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
    TABLE 54. JAPAN PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 55. JAPAN PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 56. JAPAN PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 57. CHINA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 58. CHINA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 59. CHINA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 60. AUSTRALIA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 61. AUSTRALIA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 62. AUSTRALIA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 63. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 64. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 65. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 66. LAMEA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 67. LAMEA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 68. LAMEA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 69. LAMEA PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)
    TABLE 70. LATIN AMERICA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 71. LATIN AMERICA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 72. LATIN AMERICA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 73. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)
    TABLE 74. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)
    TABLE 75. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)
    TABLE 76. ABBOTT LABORATORIES: KEY EXECUTIVES
    TABLE 77. ABBOTT LABORATORIES: COMPANY SNAPSHOT
    TABLE 78. ABBOTT LABORATORIES: PRODUCT SEGMENTS
    TABLE 79. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
    TABLE 80. ABBOTT LABORATORIES: KEY STRATERGIES
    TABLE 81. ARIEL PRECISION MEDICINE, INC.: KEY EXECUTIVES
    TABLE 82. ARIEL PRECISION MEDICINE, INC.: COMPANY SNAPSHOT
    TABLE 83. ARIEL PRECISION MEDICINE, INC.: PRODUCT SEGMENTS
    TABLE 84. ARIEL PRECISION MEDICINE, INC.: PRODUCT PORTFOLIO
    TABLE 85. ARIEL PRECISION MEDICINE, INC.: KEY STRATERGIES
    TABLE 86. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
    TABLE 87. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
    TABLE 88. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
    TABLE 89. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
    TABLE 90. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
    TABLE 91. GE HEALTHCARE,INC: KEY EXECUTIVES
    TABLE 92. GE HEALTHCARE,INC: COMPANY SNAPSHOT
    TABLE 93. GE HEALTHCARE,INC: PRODUCT SEGMENTS
    TABLE 94. GE HEALTHCARE,INC: PRODUCT PORTFOLIO
    TABLE 95. GE HEALTHCARE,INC: KEY STRATERGIES
    TABLE 96. AADI BIOSCIENCE, INC.: KEY EXECUTIVES
    TABLE 97. AADI BIOSCIENCE, INC.: COMPANY SNAPSHOT
    TABLE 98. AADI BIOSCIENCE, INC.: PRODUCT SEGMENTS
    TABLE 99. AADI BIOSCIENCE, INC.: PRODUCT PORTFOLIO
    TABLE 100. AADI BIOSCIENCE, INC.: KEY STRATERGIES
    TABLE 101. ILLUMINA, INC.: KEY EXECUTIVES
    TABLE 102. ILLUMINA, INC.: COMPANY SNAPSHOT
    TABLE 103. ILLUMINA, INC.: PRODUCT SEGMENTS
    TABLE 104. ILLUMINA, INC.: PRODUCT PORTFOLIO
    TABLE 105. ILLUMINA, INC.: KEY STRATERGIES
    TABLE 106. QIAGEN: KEY EXECUTIVES
    TABLE 107. QIAGEN: COMPANY SNAPSHOT
    TABLE 108. QIAGEN: PRODUCT SEGMENTS
    TABLE 109. QIAGEN: PRODUCT PORTFOLIO
    TABLE 110. QIAGEN: KEY STRATERGIES
    TABLE 111. ELI LILLY AND COMPANY: KEY EXECUTIVES
    TABLE 112. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
    TABLE 113. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
    TABLE 114. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
    TABLE 115. TAKEDA PHARMACEUTICAL COMPANY LTD: KEY EXECUTIVES
    TABLE 116. TAKEDA PHARMACEUTICAL COMPANY LTD: COMPANY SNAPSHOT
    TABLE 117. TAKEDA PHARMACEUTICAL COMPANY LTD: SERVICE SEGMENTS
    TABLE 118. TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT PORTFOLIO
    TABLE 119. ABBVIE INC: KEY EXECUTIVES
    TABLE 120. ABBVIE INC: COMPANY SNAPSHOT
    TABLE 121. ABBVIE INC: PRODUCT SEGMENTS
    TABLE 122. ABBVIE INC: PRODUCT PORTFOLIO
  • LIST OF FIGURES

  • FIGURE 01. PERSONALIZED MEDICINE MARKET, 2021-2031
    FIGURE 02. SEGMENTATION OF PERSONALIZED MEDICINE MARKET, 2021-2031
    FIGURE 03. TOP INVESTMENT POCKETS IN PERSONALIZED MEDICINE MARKET (2022-2031)
    FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
    FIGURE 05. LOW BARGAINING POWER OF BUYERS
    FIGURE 06. LOW THREAT OF SUBSTITUTES
    FIGURE 07. LOW THREAT OF NEW ENTRANTS
    FIGURE 08. LOW INTENSITY OF RIVALRY
    FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPERSONALIZED MEDICINE MARKET
    FIGURE 10. PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021(%)
    FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY COUNTRY 2021-2031(%)
    FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY COUNTRY 2021-2031(%)
    FIGURE 13. PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021(%)
    FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY 2021-2031(%)
    FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR INFECTIOUS DISEASE, BY COUNTRY 2021-2031(%)
    FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR NEUROLOGY OR PSYCHIATRY, BY COUNTRY 2021-2031(%)
    FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR, BY COUNTRY 2021-2031(%)
    FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
    FIGURE 19. PERSONALIZED MEDICINE MARKET, BY END USER, 2021(%)
    FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2021-2031(%)
    FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
    FIGURE 22. PERSONALIZED MEDICINE MARKET BY REGION, 2021
    FIGURE 23. U.S. PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 24. CANADA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 25. MEXICO PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 26. GERMANY PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 27. FRANCE PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 28. UK PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 29. ITALY PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 30. SPAIN PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 31. REST OF EUROPE PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 32. JAPAN PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 33. CHINA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 34. AUSTRALIA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 35. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 36. LATIN AMERICA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 37. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)
    FIGURE 38. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 42. COMPETITIVE DASHBOARD
    FIGURE 43. COMPETITIVE HEATMAP: PERSONALIZED MEDICINE MARKET
    FIGURE 44. TOP PLAYER POSITIONING, 2021
    FIGURE 45. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
    FIGURE 46. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2019-2021 ($MILLION)
    FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 50. GE HEALTHCARE,INC: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 51. GE HEALTHCARE,INC: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 52. GE HEALTHCARE,INC: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 53. AADI BIOSCIENCE, INC.: NET REVENUE, 2020-2021 ($MILLION)
    FIGURE 54. ILLUMINA, INC.: NET REVENUE, 2020-2022 ($MILLION)
    FIGURE 55. ILLUMINA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
    FIGURE 56. ILLUMINA, INC.: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 57. QIAGEN: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 58. QIAGEN: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 59. QIAGEN: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 60. ELI LILLY AND COMPANY: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 61. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 62. TAKEDA PHARMACEUTICAL COMPANY LTD: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 63. TAKEDA PHARMACEUTICAL COMPANY LTD: RESEARCH & DEVELOPMENT EXPENDITURE, 2019-2021 ($MILLION)
    FIGURE 64. TAKEDA PHARMACEUTICAL COMPANY LTD: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 65. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 66. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 67. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)

 
 

The global personalized medicine market is expected to exhibit high growth potential attributable to factors such as rise in in R&D activities in pharmaceutical industry for manufacturing of the precision medicines; increase in prevalence of cancer along with increase in incidences of various chronic disorders such as diabetes, respiratory disorders, cardiovascular disorders, and others. 

Furthermore, the personalized medicine market has gained interest of many pharmaceutical companies, owing to surge in demand for the advanced treatment procedures, due to rise in the patient pool in the regions such as North America, and

Asia-Pacific. Moreover, rise in demand for customized medicine usage in neurology, pulmonary, antiviral, and psychiatry, is offering new potential for the personalized medicine market. Moreover, there is a rise in research and development activities in the field of personalized medicine which leads to its huge adoption in the diagnosis and treatment of various diseases. Also, technological advancements in personalized medicine are anticipated to boost the market growth during the forecast period.

North America was the largest contributor to the market in terms of revenue in 2021, and Asia-Pacific is expected to witness the highest growth during the forecast period, owing to the presence of key players, rising government initiatives, developing healthcare infrastructure, and rising prevalence of chronic health issues.
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. Top companies such as Aadi Bioscience, Inc., Abbott Laboratories, ARIEL Precision Medicine, Inc., Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Takeda Pharmaceutical Company Ltd, Eli Lilly and Company, Abbvie Inc. and Qiagen.

A. Personalized medicines are the advanced diagnostic and treatment approach which is an exception for the term ‘one-size-fits-all'.

A. Rise in prevalence of chronic diseases, rise in awareness about precision medicines among people, and increase in R&D activities to develop new personalized medicines, are the major factors contributing to the growth of personalized medicine market.

A. personalized medicine diagnostics segment is the most influencing segment in personalized medicines market which is attributed to the surge in demand for personalized diagnostic services.

A. The base year is 2021 in personalized medicines market.

A. The total market value of personalized medicines market is $300.00 billion in 2021.

A. The market value of personalized medicines market in 2031 is $869.48 billion

A. The forecast period for personalized medicines market is 2022 to 2031

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Personalized Medicine Market

Start reading instantly.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers